key: cord-0259369-4u113hqg
authors: Lee, Jungmin; Vernet, Andyna; Gruber, Nathalie G.; Kready, Kasia M.; Burrill, Devin R.; Way, Jeffrey C.; Silver, Pamela A.
title: Rational engineering of an erythropoietin fusion protein to treat hypoxia
date: 2021-06-24
journal: bioRxiv
DOI: 10.1101/2021.06.24.449789
sha: 76982e17b55dba6a5dc45b6f3f0cb2be98347201
doc_id: 259369
cord_uid: 4u113hqg

Erythropoietin enhances oxygen delivery and reduces hypoxia-induced cell death, but its pro-thrombotic activity is problematic for use of erythropoietin in treating hypoxia. We constructed a fusion protein that stimulates red blood cell production and neuroprotection without triggering platelet production, a marker for thrombosis. The protein consists of an anti-glycophorin A nanobody and an erythropoietin mutant (L108A). The mutation reduces activation of erythropoietin receptor homodimers that induce erythropoiesis and thrombosis, but maintains the tissue-protective signaling. The binding of the nanobody element to glycophorin A rescues homodimeric erythropoietin receptor activation on red blood cell precursors. In a cell proliferation assay, the fusion protein is active at 10−14 M, allowing an estimate of the number of receptor–ligand complexes needed for signaling. This fusion protein stimulates erythroid cell proliferation in vitro and in mice, and shows neuroprotective activity in vitro. Our erythropoietin fusion protein presents a novel molecule for treating hypoxia.

4 challenges have limited the clinical use of EPO for tissue protection resulting from hypoxia. First, EPO has a pro-thrombotic effect that is observed at low doses, while the tissue-protective effect requires much and (E) cyan sticks (top to bottom: R103, S104, L108, Y15, R14). EPOR residues that are within 4 Å of these residues are shown in light yellow and pink sticks in (D) and (E), respectively. (F) The EPO-H fusion protein consists of the IH4 nanobody, which targets GPA-expressing cells, attached to a mutant EPO by a five-amino acid linker. (G) Mutant EPO(L108A) has weakened affinity for homodimeric EPOR, and thus, has little effect on non-target cells that lack GPA. (H) On erythropoietic target cells that express both GPA and EPOR, the binding of IH4 to GPA localizes the fusion protein to the target cell surface and allows activation of homodimeric EPOR. (I) The L108A mutation in the EPO element does not disrupt EPO interaction with CD131. As a result, IH4-EPO(L108A) can induce tissue-protective activity via a heterodimeric EPOR-CD131 receptor complex. (J) IH4-EPO(L108A) also binds to mature RBCs via GPA, thereby extending its plasma half-life. 119 120 properties: RBC production, thrombosis, tissue protection, and expected half-life. "+" = increase, "-" = 122 decrease or no effect. 

At the same time, it is important to ensure that the same mutation in the EPO element does not 125 disrupt EPO binding to heterodimers of EPOR and the co-receptor CD131 when the tissue-protective 126 activity is desired (Fig. 1I ). Several EPO mutants were designed based on previous mutagenesis studies 127 (Elliott et al., 1997; Gan et al., 2012) . The predicted behaviors of these EPO mutants, either alone or 128 when fused to an anti-GPA antibody element, are outlined in Table I . As part of the design strategy, we nanobody not only increases the size of the molecule to avoid renal clearance, but it also directs the The ability of different EPO mutants to promote RBC production was tested in vitro via TF-1 cell 151 proliferation assays. TF-1 is an immature erythroid cell line that expresses both EPOR and GPA (1620 ± darbepoetin (Table II and Fig. S1 ). The unfused EPOs with mutations on the weak face showed no 160 activity at concentrations ranging from 10 -14 to 10 -7 M, except for EPO(R103K), which had a slightly lower 161 EC 50 value compared to epoetin alfa and approximately two-fold lower efficacy (E max ) (Table II and (Table II and Fig. 2A ).

The dose-response curve of weak-face mutants fused to IH4 showed two unusual features. First, with a limited amount of the fusion protein (Fig. 2B) . At high concentrations, the fusion protein saturates

EPORs in a non-signaling, monomeric form via the strong side, and blocks receptor activation (Fig. 2C) . 

The EC 50 values of EPO(WT) and EPO(S104I) were ~1-5 nM. The EC 50 values of IH4-EPO(R103K), IH4-222 EPO(L108A) and EPO(L108A) were estimated to be ~10-20 nM (Fig. 4G) .

Although the dynamic range and the four-parameter fits varied between independent 224 experiments, these EPO variants showed reproducible effects when they were repeated several times 225 and even when they were tested under different experimental conditions (Fig. S3-S5) . When SH-SY5Y cells were pre-exposed to EPO variants 24 hr before receiving 100 µM of CoCl 2 , EPO(L108A or R103K)

In this work, we constructed an EPO fusion protein that can provide both erythropoietic and 

EPO containing the mutation L108A completely lacked in vitro erythropoietic activity, but this activity was 261 rescued when the mutant protein was fused to the GPA-targeting nanobody IH4 (Table II, 

(1992) showed that wild-type hGH inhibits signaling at >2 µM, and mutation of the weak-binding face of 297 hGH further reduces the IC 50 value to ~100 nM. They also demonstrated that the antagonistic behaviors 298 resulted from the disruption of receptor dimerization, using divalent monoclonal antibodies for hGH 299 receptors (Fuh et al., 1992) . Similarly, our fusion protein containing a weak-face EPO mutation may 300 saturate monomeric EPOR in a 1:1 stoichiometry and block the formation of a complete signaling 301 complex consisting of homodimeric EPOR, resulting in auto-inhibition of EPO signaling (Fig. 2C ).

It is important to note that while we observe an enhanced potency of IH4-EPO(L108A) in the cell 303 based assay, in our in vivo erythropoiesis experiments the potency of this molecule was similar to that of 304 darbepoetin and EPO fusion proteins that we constructed previously. In the in vitro assay, there may be 305 essentially no removal of the fusion protein, while in vivo the normal clearance mechanisms would likely 306 still operate, such as pinocytosis and degradation by Kupffer cells and/or binding to EPORs on non-307 erythroid cells and removal by non-signaling receptor-mediated endocytosis (Wiley, 2003) .

Taken together, our results indicate that IH4-EPO(L108A) could be an ideal molecule for treatment of hypoxia. The fusion protein is expected to enhance oxygen delivery and prevent hypoxia-

Turk 14